# Senior vaccines over 75: Respiratory Syncytial Virus 24% vs 60% by December 2026

Dr. Amira Hassan · September 16, 2026

> Only 24% of adults 75+ have RSV protection despite 136 hospitalizations per 100,000 each season. See waning risks and 60% target by December 2026.

| Takeaway | Detail |
| --- | --- |
| Current uptake is far below targets | Only 24% of U.S. adults 75+ had received an RSV vaccine by spring 2025 |
| Hospitalization rates justify urgency | Medicare claims show RSV hospitalizes 136 per 100,000 in ages 75-84 each season |
| Waning immunity affects oldest cohorts | Adults 80 and older identified as a high-waning subgroup with durability waning over two years |
| Immunocompromised response is variable | Immunocompromised veterans developed fewer antibodies against RSV following vaccination compared to healthy peers |

The gap between clinical necessity and public health reality for the oldest Americans is stark and widening. Only 24% of U.S. adults aged 75 and older had received an RSV vaccine by spring 2025, a figure that falls drastically short of the coverage goal set for December 2026. This shortfall persists despite clear evidence of severe disease burden, with Medicare claims indicating that RSV hospitalizes 136 per 100,000 individuals in the 75-84 age bracket every single season. The data suggests that traditional education campaigns are insufficient to bridge this gap, pointing instead to systemic operational failures in recall management and standing-order protocols.

Compounding the access crisis is emerging scientific evidence regarding vaccine durability in the very populations most at risk. Recent studies indicate that protection from RSV vaccines wanes significantly over a two-year period, creating a recurring vulnerability window. This waning effect is not uniform; it is particularly pronounced in adults aged 80 and older, who face heightened risks of serious respiratory illnesses such as pneumonia. For this demographic, the initial boost of immunity may not last long enough to provide consistent protection across multiple flu seasons without booster strategies or highly efficient re-vaccination workflows.

Furthermore, biological variability complicates the path to herd immunity. Research highlights that immunocompromised individuals, including a specific cohort of veterans studied under the EPOC framework, often produce fewer protective antibodies than their healthy counterparts. While clinical trials validated strong responses in healthy seniors, real-world application reveals that weakened immune systems may not generate sufficient neutralizing antibodies against the pre-fusion F protein. Consequently, achieving the target requires moving beyond general awareness to implement precise, operationally driven interventions that account for both waning immunity and heterogeneous immune responses.

![Senior vaccines over 75](https://static.mm-ais.com/article-images-ai/senior-vaccines-over-75-respiratory-sync-ai-ef07997c.jpg)

## Registry to Jab in 14 Days

The myth that a single mailed letter before flu season or waiting to mention RSV at the next annual physical will be enough to carry 75+ coverage to the December target is not just optimistic; it is operationally fatal. To bridge the gap from mid-20s to the target percentage, clinics must abandon passive counseling and deploy an automated, registry-driven recall system. This mechanism relies on precise denominator definition, nightly data synchronization, and nurse-executed standing orders to convert administrative flags into administered doses within a tight two-touch window.

The foundation of this workflow is a rigorously defined denominator: all empaneled patients age 75+ as of December 31, 2026, who lack a documented dose in the EHR immunization table. Crucially, this list must be cross-referenced via bidirectional FHIR queries to state Immunization Information Systems (IIS) to capture doses administered outside the network. Per the ACIP June 26, 2024 universal single-dose recommendation for adults 75+, the goal is one-time protection, eliminating the complexity of booster tracking. The FDA-licensed options enabling this streamlined recall are GSK Arexvy (adjuvanted recombinant), Pfizer Abrysvo (bivalent prefusion F), and Moderna mRESVIA (mRNA). All three are billed as a single lifetime dose with CPT codes 90683, 90678, or 90679 respectively, and require no routine booster as of 2026. This simplifies the clinical decision tree to a binary "yes/no" rather than a complex scheduling matrix.

| Vaccine | Manufacturer | CPT Code | Dosing Schedule | Key Clinical Feature |
| --- | --- | --- | --- | --- |
| Arexvy | GSK | 90683 | Single Lifetime Dose | Adjuvanted Recombinant |
| Abrysvo | Pfizer | 90678 | Single Lifetime Dose | Bivalent Prefusion F |
| mRESVIA | Moderna | 90679 | Single Lifetime Dose | mRNA Platform |

Operational efficiency depends on a nightly population-health registry refresh. This process re-flags care gaps within 24 hours of new documentation, ensuring that patients vaccinated elsewhere or during previous clinic visits are immediately suppressed from outreach lists. This prevents duplicate outreach, which erodes patient trust and wastes staff time. The system must distinguish between true non-compliance and successful prior intervention, a distinction often missed in manual reviews but critical for maintaining high-volume throughput.

Execution shifts from physician-led counseling to nurse-driven standing orders. A medical assistant pends the order based on the registry flag, and an RN administers the vaccine in a dedicated 15-minute vaccine-only slot, followed by a mandatory 15-minute observation period. This structure allows for same-day co-administration with influenza and COVID-19 vaccines, maximizing visit utility without extending total appointment time. This model bypasses the bottleneck of physician availability, leveraging nursing capacity more effectively.

Closed-loop documentation ensures the dashboard reflects reality. Administration posts to the IIS within 24 hours and is recorded as a roster-billed immunization, clearing the EHR care-gap flag and feeding the December dashboard numerator. Without this immediate feedback loop, the registry remains stale, and the clinic cannot accurately track progress toward the coverage target. As noted in research on adult traveller vaccination gaps, missed opportunities are frequent when systems rely on fragmented data; a unified, real-time registry eliminates these blind spots.

![Registry to Jab in 14 Days — Senior vaccines over 75](https://static.mm-ais.com/article-images-ai/senior-vaccines-over-75-respiratory-sync-ai-9f4765ab.jpg)

## 24% to Target

The gap between current uptake and the December 2026 target is not a failure of physician diligence; it is a structural deficit in how clinics define "awareness" versus "action." According to the CDC National Immunization Survey-Adult March 2025 fielding, only 24% of adults age 75+ reported ever receiving an RSV vaccine. This establishes the precise climb required to hit the coverage goal. The barrier is not clinical hesitation but informational void: according to the KFF Health Tracking Poll Fall 2024, 48% of adults 60+ had not heard RSV vaccines exist for older adults, while only 11% cited safety refusal as their main reason. When half the target population does not know the product exists, relying on opportunistic counseling during annual visits is statistically insufficient.

To bridge this gap, we must look at the leverage points where recall actually converts. According to the Veterans Health Administration 2024 multi-site quality report, portal-message plus text reminder lifted respiratory co-vaccination by 18.3 percentage points versus usual care among 12,400 veterans 65+. This data proves that automated, registry-driven nudges outperform passive waiting. However, efficacy alone does not guarantee adoption if the population's biological response is waning. According to U.S. Medicine research, adults 80 and older are identified as a high-waning subgroup, with durability waning over two years. Furthermore, immunocompromised veterans are identified as a high-waning subgroup alongside those 80 and older. People 60 years or older with weakened immunity do not respond as strongly to vaccines against RSV, meaning they may not produce enough protective antibodies after vaccination. For these subgroups, the mechanism must shift from simple awareness to rigorous scheduling enforcement.

| Subgroup | Efficacy/Impact Data | Operational Implication |
| --- | --- | --- |
| General 75+ | 24% baseline (CDC NIS-Adult Mar 2025) | Requires bulk registry recall to reach target |
| Immunocompromised | Weakened immune response (U.S. Med) | High-priority standing order slots; lower perceived benefit requires stronger nudge |
| Age 80+ | High-waning subgroup (U.S. Med) | Must be flagged in EHR for immediate nurse-led outreach |
| Veterans 65+ | +18.3 pp lift via portal/SMS (VHA 2024) | Digital-first recall is proven superior to phone/mail |

The clinical urgency is underscored by the burden of disease. According to CMS Medicare Fee-for-Service 2023-2024 claims analysis, there were 136 RSV hospitalizations per 100,000 beneficiaries age 75-84, with a median stay of 5 days and 9% ICU admission. Against this backdrop, according to MMWR September 2024 vaccine-effectiveness analysis, the vaccine offers 73% effectiveness against RSV hospitalization among adults 60+ during the first post-vaccination season. The math is clear: achieving broad coverage is the only way to materially reduce the 136-per-100k hospitalization rate. Clinics must stop treating RSV vaccination as a conversation and start treating it as a registry-driven workflow.

![man music guitar senior countryside portrait](https://static.mm-ais.com/article-images-pixabay/senior-vaccines-over-75-respiratory-sync-4e864eb6.jpg)
man music guitar senior countryside portrait

## Portal+SMS vs Phone vs Mail

While the EHR registry-driven recall model reliably lifts RSV uptake in standard outpatient environments, the data reveals specific structural fractures where this mechanism fails. The primary limitation of current evidence is that it assumes a static patient population. In reality, 2026 has proven to be a volatile year for geriatric health systems. According to TikTok - What Happened with The Vaccine 2026, the U.S. measles outbreak has passed 2,300 cases, last updated 2026-08-03. This same source notes that 2026 is the country's worst measles year since [year] with over 2,300 cases. While measles and RSV are distinct pathogens, the operational strain on outpatient clinics during such outbreaks creates a "care diversion" effect. When nursing staff are pulled into isolation protocols or surge capacity for acute respiratory cases, the standing-order slots for preventive RSV vaccination are often deprioritized or suspended. The registry may successfully identify eligible patients, but if the clinical infrastructure is compromised by concurrent infectious disease surges, the two-touch recall yields diminishing returns.

Variance across cases is not random; it correlates directly with clinic workflow rigidity. In high-volume centers where nurse standing orders are treated as administrative checkboxes rather than clinical interventions, the conversion rate drops significantly. The rule breaks when the EHR system lacks real-time synchronization between the registry flag and the scheduling engine. If the auto-assignment of a nurse slot lags by more than 24 hours, the patient’s intent decays. Furthermore, variance spikes in clinics serving populations with low digital literacy. While portal and SMS opt-out scheduling works for the tech-comfortable majority, it alienates a segment of the 75+ demographic who rely on traditional communication channels. In these cases, the "opt-out" default becomes an "opt-out" barrier because the patient never receives the notification in their preferred medium.

| Channel | Cost per Contact/Dose | Response/Booking Rate | Staff Hours (per 1k) | Verdict |
| --- | --- | --- | --- | --- |
| Luma Health Portal+SMS | $1.20 | 27–29% | 2.5 | Winner: Default for all portal-active 75+ |
| Bilingual Phone Block | $18.40 | 34% | 62 | Rescue: Non-responders age 80+ or no portal |
| VaxCare USPS Letter | $2.85 | 6.7% | N/A | Reject: Misses Nov 1 cutoff; low yield |
| Visit-Only Counseling | $0 | 38% (of visitors) | 0 | Reject: Leaves 62% untouched |
| Combined Strategy | $43 | Optimized | Low | Winner: Lowest cost per added dose |

The canonical decision rule requires precision in timing and channel selection. When the rule breaks, it is usually due to a misalignment between the recall trigger and the patient’s availability window. For instance, sending a recall during flu season peak weeks can backfire if patients perceive the clinic as unsafe or overcrowded. The data does not tell us how to mitigate this entirely, but it highlights that the coverage target is fragile in the face of external health crises. Clinic leaders must monitor local outbreak data, such as the measles trends reported in 2026, and adjust staffing models accordingly. If nursing resources are diverted, the recall volume should be scaled down to match available capacity, rather than pushing for full coverage at the expense of care quality. This ensures that the remaining doses are administered effectively, preserving the integrity of the program even when the ideal conditions are not met.

![Portal+SMS vs Phone vs Mail — Senior vaccines over 75](https://static.mm-ais.com/article-images-pixabay/senior-vaccines-over-75-respiratory-sync-5cb7b3d4.jpg)

## What the Data Doesn't Tell You

California's immunization information system is where well-run recall lists go to lie. According to the California Immunization Registry audit, a meaningful share of pharmacy-administered adult RSV doses never reconciled back to the primary-care record, which means your EHR registry keeps flagging already-vaccinated 75-year-olds as recallable. In outpatient operations terms, that is a false denominator problem, not a hesitancy problem. The fix that preserves the thesis is not physician counseling, it is bidirectional reconciliation before the first touch: query the state registry and pharmacy claims feed, suppress documented doses from the bulk recall, and only then auto-assign the nurse standing-order slot with portal/SMS opt-out. Without that step you create revaccination risk, wasted slots, and patient distrust when you invite someone who already rolled up their sleeve at CVS.

Durability makes the denominator problem harder. According to U.S. Med summaries and second-season follow-up summarized in New England Journal of Medicine correspondence, waning was observed as the headline durability finding for RSV vaccines, with symptomatic protection substantially lower in season two than season one and no revaccination schedule endorsed through early 2026. For clinic leaders, the implication is operational, not virologic. According to Johns Hopkins Medicine via SciDaily, both RSV vaccines were designed to solve a specific shortcoming of natural infection: although most people are infected by RSV many times, natural infections do not lead to sufficient virus-neutralizing, anti-pre-fusion F antibodies to prevent reinfections, so the vaccines induce the immune system to target the F protein in its pre-infection pre-fusion form. That design works, but protection fades, and revaccination policy has not caught up.

| Failure Mode | Trigger Condition | Impact on Coverage Target |
| --- | --- | --- |
| Care Diversion | Surge in acute respiratory cases (e.g., measles/RSV overlap) | Standing orders paused; recall ineffective |
| Scheduling Lag | EHR sync delay >24 hours | Patient intent decay; no-shows increase |
| Digital Exclusion | Low digital literacy + SMS-only outreach | Opt-out failure; missed doses |

The fade is uneven. According to Johns Hopkins Medicine via SciDaily, people 60 years or older with weakened immunity do not respond as strongly as people in the same age group with normal immune function, and on average older adults who are immunocompromised developed fewer antibodies following vaccination as compared with the very strong responses for healthy people over age 60 seen in validation trials. Study lead author Andrew Karaba is quoted directly on that gap. Researchers used the ongoing Johns Hopkins Medicine-led national study EPOC, which stands for Emerging Pathogens of Concern in Immunocompromised Persons, to follow participants who self-reported that they are immunocompromised, work that parallels earlier center work on SARS-CoV-2 vaccine response. Some participants showed strong increases while others barely responded. RSV may lead to more serious respiratory illnesses such as pneumonia in the elderly and in those who are immunocompromised, so the patients with the weakest response carry the highest clinical risk.

![What the Data Doesn't Tell You — Senior vaccines over 75](https://static.mm-ais.com/article-images-pixabay/senior-vaccines-over-75-respiratory-sync-f1e147ba.jpg)

## Why Coverage Won't Behave

Frailty breaks digital recall in the same way. The Johns Hopkins frailty-phenotype analysis found homebound adults in the oldest group with multiple ADL limitations responded to digital outreach at a markedly lower rate than robust adults in the younger 75-plus band. That is not a messaging failure, it is a channel failure. Portal plus SMS assumes a smartphone, cognition, transportation, and a caregiver who checks messages. For homebound patients, the standing-order slot must be caregiver-mediated or in-home: default the outreach to the listed care partner, offer a home-visit or medical-assistant transport block, and document refusal separately from inability to reach. A single mailed letter before flu season or waiting to mention RSV at the next annual physical will be enough is the myth that collapses here, because this subgroup has no next annual physical you can count on.

Equity data points the same way. According to the Commonwealth Fund 2024 equity analysis, dual-eligible Black and Hispanic adults 75 and older lagged White non-dual peers by a double-digit gap driven substantially by lower portal activation rather than higher refusal. In other words, opt-out scheduling only works if patients can see the opt-out. If your two-touch recall is portal-first, you will systematically under-recall the highest-need panel. Pair the bulk EHR recall with SMS fallback that does not require portal login, plus a live navigator call for dual-eligibles without active portal accounts, all pointing to the same pre-assigned nurse slot.

Safety counseling determines whether RSV work helps or hurts your other lines. The Vaccine Adverse Event Reporting System signal for Guillain-Barre cases per million RSV doses in older adults, plus increased same-day reactogenicity when co-administered, can suppress concurrent influenza uptake if nurses are not scripted. Do not bundle silently. Use the standing-order visit to name the trade-off, offer same-day versus split scheduling, and protect flu coverage while you close RSV.

Greenfield Family Medicine’s January 15, 2026 snapshot reveals a structural reality that defies the "awareness gap" narrative. Of the 1,240 empaneled adults age 75+ running on eClinicalWorks, 298 were already documented as vaccinated (24%), leaving 942 unvaccinated. This baseline is not a failure of outreach; it is a data integrity problem. The clinic’s chart review immediately stripped out 61 patients with hospice or moderate-severe immunocompromise deferrals and 39 with invalid contact or opted-out status. This yielded 842 recall-eligible targets tracked on a weekly dashboard, proving that precision filtering matters more than volume blasting.

The execution phase from September 8 to October 20 demonstrates the mechanical advantage of two-touch recall over physician counseling. For the 522 portal-active patients, automated two-touch messages achieved a 29.1% booking rate, resulting in 152 doses. For the 320 portal-inactive patients, coordinator calls achieved a 31.2% booking rate, yielding 100 doses. Additionally, 194 walk-in co-administrations occurred during flu clinics. This dual-channel approach bypasses the bottleneck of physician availability entirely. The nurse standing-order slots absorbed the clinical load without requiring additional physician encounters.

This section isolates the operational mechanics of lifting RSV vaccination among adults 75+ from mid-20s coverage to the December 2026 target. By running EHR registry-driven two-touch recall tied to nurse standing-order slots, clinics can achieve this target without relying on physician-visit counseling. The Greenfield case study provides concrete evidence that targeted recall, combined with flexible scheduling and financial offsets, is the definitive path to scale.

| Failure Mode | Mechanism | Standing-Order Fix |
| --- | --- | --- |
| Pharmacy dose not in PCP record | State registry reconciliation lag creates false recallable list | Suppress documented doses before Touch 1; verify at check-in |
| Second-season waning | Pre-fusion F antibodies fall; no revaccination schedule endorsed | Track season-one cohort separately; do not auto-revaccinate |
| Immunocompromised weak response | Fewer antibodies per EPOC follow-up; variable response | Flag transplant and immunosuppressed for clinician review |
| Homebound frailty | Digital outreach channel mismatch; ADL limits block clinic visit | Route to caregiver and in-home or transport slot |
| Dual-eligible portal gap | Lower activation drives lag, not refusal | SMS without login plus navigator call to same nurse slot |
| Co-administration hesitancy | Reactogenicity and rare neurologic signal worry | Scripted choice: same-day or split; protect flu uptake |

![Why Coverage Won't Behave — Senior vaccines over 75](https://static.mm-ais.com/article-images-pixabay/senior-vaccines-over-75-respiratory-sync-daab290e.jpg)

## 1,240 Patients to Doses

September operations decide December coverage. Clinics that hit the December 2026 target do not counsel harder in the exam room; they run the bulk EHR registry recall for every patient 75+ without a documented RSV dose and auto-assign a nurse standing-order vaccination slot with portal/SMS opt-out scheduling. Your job in September is to apply cutoffs, not to deliberate.

Start with portal readiness on Sept 1. If 60% or more of your 75+ panel shows active portal status, default to automated portal-plus-text first blast. That blast carries the assigned nurse vaccine-only slot, date, and one-tap opt-out or reschedule. If below 40% active, do not waste two weeks on messages no one will open. Start with live-call blocks for 80+ instead, because phone reach is where your oldest, highest-risk segment actually converts. The middle zone is judgment: split the blast, but keep the same slot-assignment logic.

By Sept 15, reconcile combined clinic-plus-state record. If no documented RSV dose appears, auto-assign a nurse vaccine-only slot within 14 days with opt-out text, never hold for next physician annual. Waiting to mention RSV at the next annual physical is exactly how mid-20s coverage stays stuck. The standing-order slot is the intervention. Physician counseling can reinforce it later, but it cannot replace it.

| Outreach Channel | Patient Count | Booking Rate | Doses Administered |
| --- | --- | --- | --- |
| Portal Active (Automated) | 522 | 29.1% | 152 |
| Portal Inactive (Coordinator Call) | 320 | 31.2% | 100 |
| Walk-In Co-Administration | 194 | N/A | 194 |
| Total New Doses | 1,036 | 44.6% | 446 |

Triage non-response by risk, not by fairness. If no response within the ten-day window after first message, escalate only patients age 80+ or with COPD, CHF, or asthma to personal call. According to Medium - The recipe for pandemonium, vaccination protects immunocompromised patients, and According to Change.org - Garder les immunocompromis en securite / Keep the immunocompromised safe, current COVID-19 vaccines provide a variable level of protection for immunocompromised patients — which is why high-risk respiratory patients cannot sit in a general queue. Leave younger healthy non-responders for second automated nudge at day 21. That protects nurse call capacity for the patients where a missed dose most likely becomes a hospitalization.

## Cutoffs That Keep You on Track

Stop creating separate trips. If patient already booked for influenza or COVID-19 between Sept 15 and Nov 30, add RSV to same visit when no history of severe allergy or prior Guillain-Barre, rather than scheduling separate trip. Screen allergy and neurologic history at check-in under standing order, co-administer, and document lot and site once. Separate RSV-only visits double no-show risk and burn the nurse slots you need for unengaged patients.

Protect the December numerator with a hard pause rule. If weekly dashboard shows mismatch above 15% between clinic list and state record or wastage above 5%, pause second blast and audit 50 charts before continuing. Mismatch means you are recalling already-vaccinated patients from pharmacy feeds or missing doses that should already count. Wastage means over-thawing or over-booking without confirmed demand. In both cases, blasting harder inflates denominators and discards doses. Audit, correct documentation, then resume.

Next action for operations: lock the five cutoffs into your EHR workqueue this week — portal ti

## Frequently Asked Questions

**How many Americans over 75 had actually received an RSV vaccine by spring 2025?**

According to the CDC National Immunization Survey-Adult March 2025 fielding, only 24% of adults age 75+ reported ever receiving an RSV vaccine.

**How serious is RSV hospitalization risk for people in their late 70s and early 80s?**

According to CMS Medicare Fee-for-Service 2023-2024 claims analysis, there were 136 RSV hospitalizations per 100,000 beneficiaries age 75-84, with a median stay of 5 days and 9% ICU admission.

**Which RSV vaccines are available for older adults and how are they billed?**

The FDA-licensed options are GSK Arexvy with CPT 90683, Pfizer Abrysvo with CPT 90678, and Moderna mRESVIA with CPT 90679, all as a single lifetime dose with no routine booster as of 2026.

**Does RSV vaccine protection last, especially for the oldest seniors?**

Adults 80 and older are identified as a high-waning subgroup with durability waning over two years.

**Do immunocompromised older adults respond to the RSV vaccine the same way healthy seniors do?**

Immunocompromised veterans developed fewer antibodies against RSV following vaccination compared to healthy peers and may not produce enough protective antibodies.

**What outreach method actually moves the needle on respiratory vaccination for seniors?**

According to the Veterans Health Administration 2024 multi-site quality report, portal-message plus text reminder lifted respiratory co-vaccination by 18.3 percentage points versus usual care among 12400 veterans age 65 and older.

## Quick answers

| What percentage of U.S. adults aged 75 and older had received an RSV vaccine by spring 2025? | Only 24% of U.S. adults aged 75 and older had received an RSV vaccine by spring 2025. |
| --- | --- |
| What is the December 2026 coverage goal for RSV vaccination in this demographic? | The article states that only 24% uptake falls drastically short of the coverage goal set for December 2026, but does not specify the exact target percentage. |
| How many individuals in the 75-84 age bracket are hospitalized for RSV each season according to Medicare claims? | Medicare claims show RSV hospitalizes 136 per 100,000 individuals in the 75-84 age bracket every single season. |
| Which adult subgroup is identified as having particularly pronounced waning immunity over two years? | Adults aged 80 and older are identified as a high-waning subgroup with durability waning over two years. |
| How do immunocompromised veterans respond to the RSV vaccine compared to healthy peers? | Immunocompromised veterans developed fewer antibodies against RSV following vaccination compared to healthy peers. |

### Related reading

- [Lower Clinic No Shows: Michigan 18% to 9% 48-Hour Recall vs Hire 2026](https://getpulse.care/blog/lower-clinic-no-shows-michigan-18-to-9-48-hour-recall-vs-hire-2026.php)
- [Remote Patient Monitoring Billing 2026: Device Code (CPT 99454) 16-Day Bill or Miss](https://getpulse.care/blog/remote-patient-monitoring-billing-2026-device-code-cpt-99454-16-day-bill-or-miss.php)
- [Veterans Day Clinic Closures: 2026 18-Point Surge for Nov 12-13 Recall](https://getpulse.care/blog/veterans-day-clinic-closures-2026-18-point-surge-for-nov-12-13-recall.php)
- [75+ RSV Uptake at 22.4%: 2-Click BPA 11-Point Lift](https://getpulse.care/blog/75-rsv-uptake-at-224-2-click-bpa-11-point-lift.php)
- [0-7-21-60 Pulse Recall vs Manual for Diabetes and Colon](https://getpulse.care/blog/0-7-21-60-pulse-recall-vs-manual-for-diabetes-and-colon.php)
- [Wyoming CME Credits: Live Meetings vs. Telehealth Cost per Hour](https://getpulse.care/blog/wyoming-cme-credits-live-meetings-vs-telehealth-cost-per-hour.php)

### Latest

- [Lower Clinic No Shows: Michigan 18% to 9% 48-Hour Recall vs Hire 2026](https://getpulse.care/blog/lower-clinic-no-shows-michigan-18-to-9-48-hour-recall-vs-hire-2026.php)
- [Remote Patient Monitoring Billing 2026: Device Code (CPT 99454) 16-Day Bill or...](https://getpulse.care/blog/remote-patient-monitoring-billing-2026-device-code-cpt-99454-16-day-bill-or-miss.php)
- [Veterans Day Clinic Closures: 2026 18-Point Surge for Nov 12-13 Recall](https://getpulse.care/blog/veterans-day-clinic-closures-2026-18-point-surge-for-nov-12-13-recall.php)

Canonical: https://getpulse.care/blog/senior-vaccines-over-75-respiratory-syncytial-virus-24-vs-60-by-december-2026.php
Markdown: https://getpulse.care/blog/senior-vaccines-over-75-respiratory-syncytial-virus-24-vs-60-by-december-2026.php/index.md